Coherus Oncology: Pay

Coherus Oncology paid its 3 named executives $5.1M in total in FY2025 (Dec). CEO Dennis M. Lanfear was paid $2.7M of that.

Pay$100 in the stock at the end of FY20 → $8
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Dennis M. LanfearPresident, Chief Executive Officer and Chairman of the Board of Directors
FY2025 (Dec)Not disclosed
FY2024 (Dec)Not disclosed
FY2023 (Dec)
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
5 years
Paul ReiderFormer Chief Commercial Officer
FY2025 (Dec)Not disclosed
FY2024 (Dec)Not disclosed
FY2023 (Dec)
3 years
Bryan McMichaelChief Financial Officer
FY2025 (Dec)Not disclosed
FY2024 (Dec)Not disclosed
FY2023 (Dec)
3 years

CEO pay against the pay peers

In FY2023 (Dec), the median CEO pay of the 7 peers with pay on file was $6.5M. The CEO of Coherus Oncology was paid $5.9M, 9% below the median.

  1. 1PTC Therapeutics
  2. 2Ironwood Pharmaceuticals
  3. 3Pacira BioSciences
  4. 4Mirum Pharmaceuticals
  5. 5Coherus Oncology
  6. 6Agenus
  7. 7Agios Pharmaceuticals
  8. 8Nektar Therapeutics
  9. 9Acadia PharmaceuticalsNot disclosed
  10. 10Aerie PharmaceuticalsNot disclosed
  11. 11Amicus PharmaceuticalsNot disclosed
  12. 12Collegium PharmaceuticalsNot disclosed
  13. 13Corcept TherapeuticsNot disclosed
  14. 14Deciphera PharmaceuticalsNot disclosed
  15. 15Dynavax TechnologiesNot disclosed
  16. 16Eagle PharmaceuticalsNot disclosed
  17. 17FibrogenNot disclosed
  18. 18Heron TherapeuticsNot disclosed
  19. 19Intercept PharmaceuticalsNot disclosed
  20. 20Karyopharm TherapeuticsNot disclosed
  21. 21Supemus PharmaceuticalsNot disclosed
  22. 22Vanda PharmaceuticalsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.